<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/50E890D6-F258-4931-B53D-3FCC2C6EC679"><gtr:id>50E890D6-F258-4931-B53D-3FCC2C6EC679</gtr:id><gtr:name>Advanced Bioprocess Services Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8099FCB6-4E2E-4AF2-87D5-A1F8919B2668"><gtr:id>8099FCB6-4E2E-4AF2-87D5-A1F8919B2668</gtr:id><gtr:name>Advanced Bioprocess Design Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF"><gtr:id>CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF</gtr:id><gtr:name>Loughborough University</gtr:name><gtr:department>Wolfson Sch of Mech, Elec &amp; Manufac Eng</gtr:department><gtr:address><gtr:line1>Loughborough University</gtr:line1><gtr:line4>Loughborough</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE11 3TU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF"><gtr:id>CAA9A40D-0226-4A4F-AC0D-D8299E30A1EF</gtr:id><gtr:name>Loughborough University</gtr:name><gtr:address><gtr:line1>Loughborough University</gtr:line1><gtr:line4>Loughborough</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE11 3TU</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/50E890D6-F258-4931-B53D-3FCC2C6EC679"><gtr:id>50E890D6-F258-4931-B53D-3FCC2C6EC679</gtr:id><gtr:name>Advanced Bioprocess Services Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8099FCB6-4E2E-4AF2-87D5-A1F8919B2668"><gtr:id>8099FCB6-4E2E-4AF2-87D5-A1F8919B2668</gtr:id><gtr:name>Advanced Bioprocess Design Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2385760-DE2E-4D45-A611-DEB951931E81"><gtr:id>E2385760-DE2E-4D45-A611-DEB951931E81</gtr:id><gtr:name>Scottish National Blood Transfusion Service (SNBTS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7D3EA30-37F2-4BC2-9769-8BCF2DFFBB7E"><gtr:id>C7D3EA30-37F2-4BC2-9769-8BCF2DFFBB7E</gtr:id><gtr:name>Fred Hutchinson Cancer Research Centre</gtr:name><gtr:address><gtr:line1>Fred Hutchinson Cancer Research Centre</gtr:line1><gtr:line2>1100 Fairview Avenue North</gtr:line2><gtr:line3>D5-280</gtr:line3><gtr:line4>Seattle</gtr:line4><gtr:line5>Washington</gtr:line5><gtr:postCode>WA 98109</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DA78ACB5-9A2A-4125-B571-650E8671C3D4"><gtr:id>DA78ACB5-9A2A-4125-B571-650E8671C3D4</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FK00705X%2F1"><gtr:id>EE0B042E-58B8-4680-9B17-2F4C81E22CB8</gtr:id><gtr:title>Engineering Biological Science - Processes and Systems for Haematopoietic Stem Cell Based Therapy Manufacture</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>EP/K00705X/1</gtr:grantReference><gtr:abstractText>Umbilical cords are traditionally discarded after childbirth as medical waste. However, over the past few decades it has become apparent that the cord contains a small amount of immature blood cells with powerful properties to repair the human body. Cord blood is now frequently used instead of bone marrow to treat childhood blood cancers (leukaemia). Cord blood cells can also be grown to generate very large numbers of red blood cells or platelets for transfusion, or, if processed differently to create immune system cells. More recently cord blood has been proven effective, or is being clinically trialled, for a wide range of serious conditions such as organ failure, childhood brain damage or diabetes. 

Despite national cord blood collection and banking programmes since the early 1990's, the success of these new clinical applications will lead to unsustainable demand on already strained stocks of cord blood. In this Fellowship I intend to develop tools to help manufacture large quantities of medicinally valuable cord blood cells from the small samples retrieved at child birth. This will form the basis of a manufactured blood related bio-products industry.

We will use a new technology to grow the cells in small vessels under very controlled conditions. These vessels will let us quickly and efficiently test different physical conditions (such as oxygen and acidity) and novel chemical additives on the growth of the blood cells. We will use engineering approaches to control the cells' environment in novel ways, and understand the relationships between the cells' development. We will demonstrate the conditions and systems that are necessary to grow these cells to large and clinically useful numbers. We will also understand how tolerant the manufacturing process is for repeated production of safe and effective cells.
 
My proposed research will help the clinical community deliver a new cohort of treatments for serious diseases to patients in the UK as well as help develop an important new economic activity in the UK in the development of these new types of cell based therapies.</gtr:abstractText><gtr:potentialImpactText>Ex vivo control of proliferation and development of HSCs will create the opportunity for rapid clinical impact for patients suffering from haematological malignancies through a safe and unlimited supply of immunologically matched and consistent quality cells engineered to increase engraftment speed and decrease mortality. It will provide the scientific basis for a fully self-replenishing input cell supply for industrial production of naturally occurring haematopoietic lineages or haematopoietic cells engineered for therapeutic effect. This 'productisation' of cells will drive down costs for health service suppliers, create a manufacturing paradigm with sufficient economic return for product manufacturers, contribute to economic growth in a strategic area for the UK economy (high value bio-manufacturing), and create a UK technology based industry for export. It will bolster research into other therapeutic applications, such as organ support, through offering reproducible cells specifications for clinical trials. It will hasten the reality of manufactured cellular blood products and their manipulation for diverse therapeutic outcomes. The science developed will provide a powerful case study of the potential of interdisciplinary research and provide a pathway for other complex cell therapy developments with detrimental emergent parameters in bio-manufacture.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2013-09-30</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1294482</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish National Blood Transfusion Service (SNBTS)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Scottish National Blood Transfusion Service (Manufactured Blood Clinical Trial Development)</gtr:description><gtr:id>926A97F2-87D2-450D-BDB9-DD2CB8E4C43B</gtr:id><gtr:impact>Multidisciplinary; Cell biology, Clinical Haematology, Process Engineering, Manufacturing Engineering

Main impact was the generation of data required to successfully bid for Wellcome Trust Translational Award (reported under separate section)</gtr:impact><gtr:outcomeId>5464a274856f10.25827097-1</gtr:outcomeId><gtr:partnerContribution>Providing the laboratory based process to use in the scaled system, and providing cells and reagents at the appropriate point of differentiation to be compatible with the scalable manufacturing systems.</gtr:partnerContribution><gtr:piContribution>Generating proof of concept data regarding scaled manufacturing of red blood cells to enable subsequent application for a full Wellcome Trust Translational Award</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advanced Bioprocess Services Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Advanced Bioprocess Services</gtr:description><gtr:id>5E893A6E-9368-4381-97C1-2FF7DEBEF367</gtr:id><gtr:impact>Novel industrially applied processes</gtr:impact><gtr:outcomeId>58b05797b1e720.59493697-1</gtr:outcomeId><gtr:partnerContribution>Advanced Bioprocess Services manage the interface with companies seeking process development and provide extensive high value reagents and consumables for project work, either directly or via other collaborating companies, as well as providing access to the most relevant and protected industrial processes for development of our research.</gtr:partnerContribution><gtr:piContribution>We have partnered with Advanced Bioprocess Services to deliver technology and process development expertise to clinical stage therapeutic product companies. These have included pre-clinical bioreactor process development for a Boston (US) based blood products company, and process development for a leading UK based neural stem cell company. Our contribution has been specifically in novel process model development, novel methods to improve process efficiency, and technology design.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Haematology</gtr:department><gtr:description>Megakaryocyte Culture for Platelet production</gtr:description><gtr:id>25937078-343B-4B4B-8503-73A2CC62E6F4</gtr:id><gtr:impact>Data on megakaryocyte growth dynamics and influences; outputs in preperation</gtr:impact><gtr:outcomeId>56a8b6256b1212.53487355-1</gtr:outcomeId><gtr:partnerContribution>Our partners have produced genetically modified megakaryocytes that can proliferate in a relatively stable form over a long period. They have generated cell stocks for us, transferred analytical protocols and provided training, and provided scientific and technical advice.</gtr:partnerContribution><gtr:piContribution>We are taking a novel cell type (as described below) and culturing in a scalable production system. We are applying a novel software based modelling approach to define optimal process operation.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Advanced Bioprocess Design Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Advanced Bioprocess Design Ltd</gtr:description><gtr:id>0E00ECFD-992F-444B-9D0E-8EB441655B38</gtr:id><gtr:impact>Multiple evolutions of the new software tool, StemCellCAD. 

The collaboration is highly interdisciplinary involving cell culture biologists, bio-manufacture engineering, mathematical modelling, and software development.</gtr:impact><gtr:outcomeId>58b05ac1471c57.32863829-1</gtr:outcomeId><gtr:partnerContribution>Advanced Bioprocess Design provide extensive and free engineering and software development time input - approximately 20 days a year - for modelling support and user specified Software changes. The company also provide heavily subsidized access to the software which we use across a wide range of projects and teaching.</gtr:partnerContribution><gtr:piContribution>The partnership is built around a novel software product developed by Advanced Bioprocess Design Ltd for dynamic mechanistic modelling of cell culture systems, particularly for manufacture design. We are the partner research group for the company and have provided software design input, user requirement feedback, and testing of model development in specific relevant processes. We are generating a co-publication strategy of modelling workflow and exemplars for manufacturing in regenerative medicine.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>45420</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early Career Forum Call</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/L015404/1</gtr:fundingRef><gtr:id>2EE5D97E-DDA8-4D8A-886A-B2147A53EF3C</gtr:id><gtr:outcomeId>5464a39540d8a0.79835488</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3916</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRACKIT [UK Industry]</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>F350E52E-EA67-4731-B083-C04C29D487F2</gtr:id><gtr:outcomeId>58b0634e2f6e54.76620237</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>573461</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Translation Award</gtr:department><gtr:description>Wellcome Trust Translational Award</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>80A5D540-40ED-4DE8-8F11-F3B2102C5BB2</gtr:id><gtr:outcomeId>546378b368db26.36982180</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>143138</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FUTURE MANUFACTURING HUB IN TARGETED HEALTHCARE</gtr:description><gtr:end>2023-12-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:fundingRef>EP/P006485/1</gtr:fundingRef><gtr:id>78A012D5-116E-4EE7-8777-E7B1956DF2B7</gtr:id><gtr:outcomeId>58b064bd8f51a8.09349372</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The efficiency and control outcomes that we are demonstrating in cell culture in the academic setting have shown the potential to significantly reduce bio-manufacturing run times and to dramatically reduce total volume requirements. Our findings are currently being applied by a US based partner company to build an efficient manufacturing process for a very high dose cell based therapeutic product. The impact of our work will make the difference between unfeasible final manufacturing costs and a product that will have real clinical impact. The work is also being evaluated by selected UK partners for potential exploitation. Our ambition is that as the modelling and process design approaches we are developing are demonstrated in these early real world industrial case studies that the evident benefits will lead to wider take up across the industry.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>13251E85-88A5-4FE1-BF67-B1BA70885361</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56d430c0e026b6.72414879</gtr:outcomeId><gtr:sector>Manufacturing, including Industrial Biotechology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>This research is aimed at improving our understanding of growing different types of blood cells outside the body. The research program is still active but has now generated a number of key findings and outcomes. Firstly we have developed a method for immobilizing expensive and potent blood cell mediators in bioreactors - this means we can greatly reduce the cost and increase the control of culturing these cells over a wide range of scales. Secondly, we have collaborated with a commercial partner, Advanced Bioprocess Design Ltd, to develop a software interface and framework for generating dynamic mathematical models of these culture systems. This approach and software is now in use with several companies making new clinical products. Thirdly we have identified critical factors in the cell culture environment that restrict the efficiency of the cell culture system; in combination with our modelling this has enables us to dramatically improve the volumetric efficiency of these culture systems.</gtr:description><gtr:exploitationPathways>These findings are already being explored by industrial partners for improved manufacturing control and particularly for improved economics in bioproduction.</gtr:exploitationPathways><gtr:id>4FE36513-4245-421D-A8EB-F9D0BA9CCCA8</gtr:id><gtr:outcomeId>56d4307c586f13.76891539</gtr:outcomeId><gtr:sectors><gtr:sector>Manufacturing, including Industrial Biotechology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>The tool is currently under evaluation for IP protection. However, it is a method for enabling presentation of growth factors into a standard industry bioreactor where factors are required at far lower levels than previously reported, and where factors can be introduced and removed non-invasively.</gtr:description><gtr:id>32714513-29EB-4076-8AA0-97C4A93C27B9</gtr:id><gtr:impact>Provision of tool will be provided after IP protection</gtr:impact><gtr:outcomeId>56a8bb321d5e93.59601737</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Controllable Biological Signalling</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>This is a software package that allows conceptual description and linking of the dynamics of species in a system. It is tailored for advanced cell human cell cultures so includes common behaviours such as growth, decay, promotion, inhibition amongst others and enables specification of common arising dynamic phenomena such as feedback loops. The software allows data fitting to described models and sensitivity analysis.</gtr:description><gtr:id>96D86FB6-A530-4556-853B-1E605EE600DC</gtr:id><gtr:impact>The software product was developed in collaboration with Advanced Bioprocess Design Ltd. ABD developed the software to meet our modelling requirements and supported us through multiple case studies. The software is now being applied in a range of academic and industrial programmes to generate models of a range of culture systems; this has defined further experimental work and identified mechanistic behaviours and operational risks. Outputs in preparation.</gtr:impact><gtr:outcomeId>56a8bc0e4f5112.48849076</gtr:outcomeId><gtr:title>StemCellCAD</gtr:title><gtr:type>Software</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>71545118-866E-427C-99B4-154C335A5FD0</gtr:id><gtr:title>The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors.</gtr:title><gtr:parentPublicationTitle>Journal of tissue engineering and regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4435dd6e5a4d21c53bcbaa144ef23c6"><gtr:id>f4435dd6e5a4d21c53bcbaa144ef23c6</gtr:id><gtr:otherNames>Bayley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6254</gtr:issn><gtr:outcomeId>58aad1b55a7d97.79853852</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85ED6226-2B86-46DE-A454-60B60C406888</gtr:id><gtr:title>Immobilized hematopoietic growth factors onto magnetic particles offer a scalable strategy for cell therapy manufacturing in suspension cultures.</gtr:title><gtr:parentPublicationTitle>Biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e494ae89f41381773a500b8a127f005b"><gtr:id>e494ae89f41381773a500b8a127f005b</gtr:id><gtr:otherNames>Worrallo MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1860-6768</gtr:issn><gtr:outcomeId>58aad1b5854dd6.50973821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F16A40AF-8F0B-4E49-A6D8-EEEB22BEB27A</gtr:id><gtr:title>Translating Cell-Based Regenerative Medicines from Research to Successful Products: Challenges and Solutions</gtr:title><gtr:parentPublicationTitle>Tissue Engineering Part B: Reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4aad245a752494faf4852585e04783f5"><gtr:id>4aad245a752494faf4852585e04783f5</gtr:id><gtr:otherNames>Bayon Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1937-3368</gtr:issn><gtr:outcomeId>5463576ad1b552.86157931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>564504AB-FD8C-4423-B0FB-DA2DE7E2C954</gtr:id><gtr:title>Experimentally integrated dynamic modelling for intuitive optimisation of cell based processes and manufacture</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96aa440190b56e95435e4d1482c46e2b"><gtr:id>96aa440190b56e95435e4d1482c46e2b</gtr:id><gtr:otherNames>Stacey A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a821c7d8dfc74.10614400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ECBC1A7E-AB5B-4321-A53D-73ADA134112C</gtr:id><gtr:title>Immobilisation of Delta-like 1 ligand for the scalable and controlled manufacture of hematopoietic progenitor cells in a stirred bioreactor.</gtr:title><gtr:parentPublicationTitle>BMC biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91e95d710f2066d5d180d33b50a4788d"><gtr:id>91e95d710f2066d5d180d33b50a4788d</gtr:id><gtr:otherNames>Moore RLL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1472-6750</gtr:issn><gtr:outcomeId>5a2fe5f4886980.26064953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A85DAF1D-AEFB-43B5-B094-23004CFE187A</gtr:id><gtr:title>A mechanistic model of erythroblast growth inhibition providing a framework for optimisation of cell therapy manufacturing</gtr:title><gtr:parentPublicationTitle>Biochemical Engineering Journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/db34b00b4e5428ddbb990e2317128f91"><gtr:id>db34b00b4e5428ddbb990e2317128f91</gtr:id><gtr:otherNames>Glen K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a821c7d520221.27888441</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/K00705X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>